Imunon Announces Positive Data From Phase 2 Trial Of IMNN-001 In Advanced Ovarian Cancer, Stock Down

(RTTNews) - Imunon, Inc. (IMNN), Thursday announced positive data from the Phase 2 OVATION 2 Study of IMNN-001, its investigational interleukin-12 or IL-12 immunotherapy for the treatment of advanced ovarian cancer.

The study assessed the safety and efficacy of IMNN-001 plus neoadjuvant and adjuvant chemotherapy or NACT of paclitaxel and carboplatin compared to standard-of-care NACT alone.

The findings showed that participants treated with IMNN-001 plus standard-of-care NACT lived 11.1 months longer than patients treated with NACT alone.

Moreover, the IMNN-001 treatment gave better surgical outcomes, showed improvement in progression-free survival, and was well tolerated in the patients.

The biotechnology company is also planning an end-of-Phase 2 in-person meeting with the FDA to discuss plans for the Phase 3 pivotal trial, expected to start in the first quarter of next year.

Currently, Imunon's stock is dropping 8.14 percent, to $0.86 on the Nasdaq.